Click on image to view larger version.

Figure 3 Irbesartan decreases production of superoxide in the neutrophils of patients with coronary artery disease. Serum samples were collected from the patients who were placed on placebo or irbesartan (150 mg/day) for a 12-week period. Samples were collected at the start of the study (0 weeks) and at 4 and 12 weeks of treatment. The neutrophils were isolated and the peak levels of superoxide production after neutrophil respiratory burst were performed. The p value was <0.0001, as determined by analysis of variance, for time, for group and for the group-time interaction. Black diamond = placebo; black square = irbesartan; *p < 0.05 = difference between 0 and 4 or 12 weeks within each group; #p < 0.05 = difference between placebo and irbesartan groups.